Sakai Tamami, Hara Johsuke, Yamamura Kenta, Abo Miki, Okazaki Akihito, Ohkura Noriyuki, Kasahara Kazuo
Respiratory Medicine, Kanazawa University Hospital, Ishikawa, Japan.
Turk Thorac J. 2020 Mar 1;21(2):75-79. doi: 10.5152/TurkThoracJ.2019.18100. Print 2020 Mar.
Chronic obstructive pulmonary disease (COPD) increases the risk of lung cancer. The relationships between COPD and Asthma COPD Overlap (ACO), and between the histopathological types of lung cancer and driver mutations remain unclear and need further study. The aim of this retrospective study was to examine the relationships between the histopathological type, frequency of epidermal growth factor receptor (EGFR) driver mutations, and anaplastic lymphoma receptor tyrosine kinase (ALK) rearrangements in the lung cancers of patients with COPD and ACO.
Patients with pure COPD (n=198) or ACO (n=318) who were admitted to our hospital were reviewed retrospectively.
Lung cancers were identified in 43 (21.7%) patients with pure COPD and 54 (17.0%) patients with ACO. The following lung cancers types were observed: patients with pure COPD had 19 (44.2%) adenocarcinomas, 13 (30.2%) squamous cell lung carcinomas (SCC), 8 (18.6%) small cell lung carcinomas (SCLC); patients with ACO had 23 (42.6%) adenocarcinomas, 23 (42.6%) SCC, 2 (3.70%) SCLC. SCLC was significantly more prevalent in patients with pure COPD (p<0.05) than in those with ACO. Differences between the numbers of other histological types of lung cancer and the numbers of driver mutations in the 2 groups of patients were not significant.
The differences in the rate of lung cancer and prevalence of EGFR driver mutations between the patients with pure COPD and those with ACO were not significant.
慢性阻塞性肺疾病(COPD)会增加患肺癌的风险。COPD与哮喘-COPD重叠综合征(ACO)之间的关系,以及肺癌的组织病理学类型与驱动基因突变之间的关系仍不明确,需要进一步研究。这项回顾性研究的目的是探讨COPD和ACO患者肺癌的组织病理学类型、表皮生长因子受体(EGFR)驱动基因突变频率与间变性淋巴瘤激酶(ALK)重排之间的关系。
回顾性分析我院收治的单纯COPD患者(n = 198)和ACO患者(n = 318)。
43例(21.7%)单纯COPD患者和54例(17.0%)ACO患者被确诊为肺癌。观察到以下肺癌类型:单纯COPD患者中,腺癌19例(44.2%),肺鳞状细胞癌(SCC)13例(30.2%),小细胞肺癌(SCLC)8例(18.6%);ACO患者中,腺癌23例(42.6%),SCC 23例(42.6%),SCLC 2例(3.70%)。单纯COPD患者的SCLC明显比ACO患者更常见(p<0.05)。两组患者其他组织学类型肺癌的数量与驱动基因突变数量之间的差异不显著。
单纯COPD患者与ACO患者之间肺癌发生率和EGFR驱动基因突变率的差异不显著。